Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $19.50.
A number of analysts have commented on ENTA shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen cut Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 22nd.
Check Out Our Latest Report on Enanta Pharmaceuticals
Enanta Pharmaceuticals Price Performance
Shares of NASDAQ ENTA opened at $13.60 on Monday. The firm has a market cap of $396.03 million, a price-to-earnings ratio of -5.64 and a beta of 0.98. The company's 50-day simple moving average is $13.59 and its 200-day simple moving average is $13.48. Enanta Pharmaceuticals has a 52-week low of $7.05 and a 52-week high of $17.15.
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The firm had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. Equities research analysts anticipate that Enanta Pharmaceuticals will post -2.36 EPS for the current fiscal year.
Institutional Trading of Enanta Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $32,000. Seven Fleet Capital Management LP acquired a new position in Enanta Pharmaceuticals in the 4th quarter valued at about $36,000. Legal & General Group Plc purchased a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at approximately $41,000. Strs Ohio acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $50,000. Finally, Clearstead Trust LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $74,000. 94.99% of the stock is owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Company Profile
(
Get Free Report)
Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.
Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Enanta Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.
While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
